Microbix Biosystms (TSE:MBX) has released an update.
Microbix Biosystems Inc. has enhanced its test-ingredient production by successfully extending bioreactor use to a second major Antigen, improving its manufacturing capacity and efficiency. This development not only increases the production volume of clinically significant antigens used in diagnostic immunoassays but also demonstrates the company’s commitment to innovation and continuous improvement following the demand fluctuations experienced during the COVID-19 pandemic.
For further insights into TSE:MBX stock, check out TipRanks’ Stock Analysis page.
